SEC Filing Summary

Mitchel Sayare, a director at Altimmune, Inc., was granted 48,800 stock options with an exercise price of $2.82 per share on May 1, 2026. These options are part of the company's non-employee director compensation policy. The options vest over 12 months, with substantially equal monthly installments beginning May 1, 2026, contingent upon continued service. The options have an expiration date of May 1, 2036. This filing is a Form 4, indicating a change in beneficial ownership.